IL135622A0 - Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps - Google Patents

Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Info

Publication number
IL135622A0
IL135622A0 IL13562298A IL13562298A IL135622A0 IL 135622 A0 IL135622 A0 IL 135622A0 IL 13562298 A IL13562298 A IL 13562298A IL 13562298 A IL13562298 A IL 13562298A IL 135622 A0 IL135622 A0 IL 135622A0
Authority
IL
Israel
Prior art keywords
tyrosine kinase
kinase inhibitors
quinazoline derivatives
colonic polyps
treating colonic
Prior art date
Application number
IL13562298A
Other languages
English (en)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL135622A0 publication Critical patent/IL135622A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13562298A 1997-11-06 1998-11-04 Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps IL135622A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508497A 1997-11-06 1997-11-06
PCT/US1998/023549 WO1999024037A1 (en) 1997-11-06 1998-11-04 Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Publications (1)

Publication Number Publication Date
IL135622A0 true IL135622A0 (en) 2001-05-20

Family

ID=25509419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13562298A IL135622A0 (en) 1997-11-06 1998-11-04 Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Country Status (15)

Country Link
EP (1) EP1039910A1 (xx)
JP (1) JP2001522802A (xx)
KR (1) KR20010031813A (xx)
CN (1) CN1278176A (xx)
AR (1) AR016415A1 (xx)
AU (1) AU1308799A (xx)
BR (1) BR9814116A (xx)
CA (1) CA2306155A1 (xx)
HU (1) HUP0004286A3 (xx)
IL (1) IL135622A0 (xx)
NO (1) NO20002166L (xx)
NZ (1) NZ503991A (xx)
PL (1) PL340800A1 (xx)
WO (1) WO1999024037A1 (xx)
ZA (1) ZA9810134B (xx)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006876B1 (ru) * 1999-08-12 2006-04-28 Уайт Холдингз Корпорейшн Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
JP4724657B2 (ja) 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド プロセス
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
UA85706C2 (xx) 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-феніламінохіназолін-6-іламіди$4-фениламинохиназолин-6-иламиды
JP4881875B2 (ja) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物
JP2010503407A (ja) 2006-09-12 2010-02-04 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
WO2009092052A2 (en) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Methods and compositions for treating polyps
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DK2245026T3 (da) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
AR079984A1 (es) 2010-01-12 2012-03-07 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
WO2011113802A2 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
WO2011130654A1 (en) 2010-04-16 2011-10-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2013005445A (es) 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
ES2573336T3 (es) 2011-08-12 2016-06-07 F. Hoffmann-La Roche Ag Compuestos de indazol, composiciones y métodos de uso
RU2014109093A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Антитела против нейрегулина и их применение
CN103827115A (zh) 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
CN105246508A (zh) 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
WO2015049325A1 (en) 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
KR20160070136A (ko) 2013-10-18 2016-06-17 제넨테크, 인크. 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN105934253A (zh) 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
SG11201608106PA (en) 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
CN107912040B (zh) 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
US20160161485A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
AU2015343494A1 (en) 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107531690B (zh) 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
RU2710735C2 (ru) 2014-12-23 2020-01-10 Дженентек, Инк. Композиции и способы лечения и диагностики резистентного к химиотерапии рака
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
JP6855379B2 (ja) 2015-01-09 2021-04-07 ジェネンテック， インコーポレイテッド 癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
WO2016112251A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
WO2016112298A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
EP3280736A1 (en) 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
CA2983282A1 (en) 2015-05-12 2016-11-17 Genentech, Inc. Therapeutic and diagnostic methods for cancer
KR20180012753A (ko) 2015-05-29 2018-02-06 제넨테크, 인크. 암에 대한 치료 및 진단 방법
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
US10208056B2 (en) 2015-08-26 2019-02-19 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
UA124573C2 (uk) 2015-09-25 2021-10-13 Дженентек, Інк. Антитіло, яке специфічно зв'язується з tigit людини, та спосіб лікування або сповільнення прогресування раку у суб'єкта
HRP20220227T1 (hr) 2015-12-16 2022-04-29 Genentech, Inc. Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
CN114395624A (zh) 2016-02-29 2022-04-26 基因泰克公司 用于癌症的治疗和诊断方法
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
CN109154027A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
WO2017205538A1 (en) 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
WO2017214373A1 (en) 2016-06-08 2017-12-14 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
CN110267678A (zh) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2019084395A1 (en) 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
CA3100200A1 (en) 2018-05-21 2019-11-28 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
SG11202012446UA (en) 2018-06-23 2021-01-28 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
CN112955747A (zh) 2018-09-19 2021-06-11 豪夫迈·罗氏有限公司 膀胱癌的治疗和诊断方法
ES2955032T3 (es) 2018-09-21 2023-11-28 Hoffmann La Roche Métodos de diagnóstico para el cáncer de mama triple negativo
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
JP2022519649A (ja) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド がんの診断および治療方法
WO2020172712A1 (en) 2019-02-27 2020-09-03 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021046159A1 (en) 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230024096A1 (en) 2019-10-29 2023-01-26 Hoffmann-La Roche Inc. Bifunctional compounds for the treatment of cancer
JP2022553803A (ja) 2019-11-06 2022-12-26 ジェネンテック， インコーポレイテッド 血液がんの処置のための診断方法及び治療方法
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
AU2020408562A1 (en) 2019-12-20 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CA3165187A1 (en) 2020-01-27 2021-08-05 Catherine LAI Methods for treatment of cancer with an anti-tigit antagonist antibody
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
BR112022025801A2 (pt) 2020-06-18 2023-10-03 Hoffmann La Roche Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP2023544450A (ja) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド 三環式ピリドン及びピリミドン
IL301547A (en) 2020-10-05 2023-05-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CR20230382A (es) 2021-02-12 2023-09-06 Hoffmann La Roche Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
TW202313633A (zh) 2021-05-25 2023-04-01 美商伊瑞斯卡公司 含硫雜芳族三環ｋｒａｓ抑制劑
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024085242A2 (en) 2022-10-21 2024-04-25 Kawasaki Institute Of Industrial Promotion Non-fouling or super stealth vesicle
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
ZA9810134B (en) 2000-05-05
AR016415A1 (es) 2001-07-04
WO1999024037A1 (en) 1999-05-20
NO20002166D0 (no) 2000-04-27
BR9814116A (pt) 2000-10-03
CN1278176A (zh) 2000-12-27
HUP0004286A3 (en) 2002-01-28
PL340800A1 (en) 2001-02-26
AU1308799A (en) 1999-05-31
NZ503991A (en) 2001-11-30
NO20002166L (no) 2000-06-28
CA2306155A1 (en) 1999-05-20
HUP0004286A2 (hu) 2001-11-28
KR20010031813A (ko) 2001-04-16
JP2001522802A (ja) 2001-11-20
EP1039910A1 (en) 2000-10-04

Similar Documents

Publication Publication Date Title
IL135622A0 (en) Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
IL134013A0 (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
EG24381A (en) Tyrosine kinase inhibitors
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
PL348605A1 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
HUP0201935A3 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
GB9501567D0 (en) Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
EP1161433A4 (en) TYROSINE KINASE INHIBITORS
PL331221A1 (en) Heteroaromatic bicyclic compounds as inhibitors of propteinous tyrosine kinase
HK1049154A1 (zh) 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮
AP2000001861A0 (en) Bicylic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9604361D0 (en) 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
PL331154A1 (en) Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
ZA986729B (en) Irreversible inhibitors of tyrosine kinases
IL142121A0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
HUP0203162A3 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
IL123124A0 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9600997D0 (en) N-indolinyl-pyridopyrimidines as tyrosine kinase inhibitors
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
GB9524131D0 (en) Pyrido-pyrimidine compounds as tyrosine kinase inhibitors